AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling glycaemia in type II diabetes but has failed to show a benefit in terms of cardiovascular outcomes. At the European Society of Cardiology Annual Congress Dr Deepak Bhatt MD, Professor of Medicine at Harvard Medical School and Chief of Cardiology, VA Boston Healthcare System Brigham and Women’s Hospital explains that this agent should be a useful addition in second and third line treatment.
You may also like...
Raw Deal for European Women with Coronary Artery Disease 12 Sep, 2005 Lytics before PCI: ASSENT Denied 17 Nov, 2005 “NIHSS-Plus”: Improvement on National Institutes of Health Stroke Scale? 9 Feb, 2007 Surgical Ventricular Reconstruction—No Benefit On Top Of Coronary Artery Bypass Grafting In Patients With Severe Heart Failure 1 Apr, 2009
- Previous story Novel oral anticoagulants: latest opinion from the ESC congress
- Next story AudioMedica.com with MDFM: Novel oral anticoagulants: latest opinion from the ESC congress
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014